PMV Pharmaceuticals, Inc. (PMVP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in PMV Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

PMV Pharmaceuticals, Inc. (PMVP) has returned -0.80% so far this year and 13.76% over the past 12 months.

Based on dividend-adjusted daily data since Sep 25, 2020, PMVP's average daily return is -0.12%, while the average monthly return is -2.11%.

Historically, 37% of months were positive and 63% were negative. The best month was Dec 2020 with a return of +74.6%, while the worst month was Oct 2023 at -75.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, PMVP closed higher 46% of trading days. The best single day was Nov 1, 2023 with a return of +31.1%, while the worst single day was Oct 12, 2023 at -47.6%.

PMV Pharmaceuticals, Inc. has an annualized alpha of -37.51%, beta of 1.18, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since September 28, 2020.

• This stock participated in 225.57% of S&P 500 Index downside but only 0.04% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PMVP ranks 49 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for PMV Pharmaceuticals, Inc. (PMVP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the PMV Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the PMV Pharmaceuticals, Inc. was 98.64%, occurring on May 15, 2025. The portfolio has not yet recovered.

The current PMV Pharmaceuticals, Inc. drawdown is 97.98%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of PMV Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how PMV Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.